INTRODUCTION: We aimed to determine the effect of comorbidities on covert hepatic encephalopathy (CHE) diagnosis and overt hepatic encephalopathy (OHE) development. METHODS: Cirrhotic outpatients underwent CHE testing and 2-year follow-up. Cox regression was performed for time to OHE. In total, 700 patients (60 years, 84% men, model for end-stage liver disease 11) and 33% prior OHE underwent testing and follow-up. RESULTS: Major comorbidities were hypertension (54%), diabetes (35%), and depression (29%). Common medications were proton pump inhibitor (49%), beta-blockers (32%), and opioids (21%). Approximately 90 (40%) prior-OHE patients developed recurrence 93 (30,206) days post-testing predicted only by liverrelated variables. DISCUSSION: Demographics, cirrhosis characteristics, and opioid use, but not other comorbid conditions, were associated with CHE diagnosis and OHE progression.
INTRODUCTION: We aimed to determine the effect of comorbidities on covert hepatic encephalopathy (CHE) diagnosis and overt hepatic encephalopathy (OHE) development. METHODS: Cirrhotic outpatients underwent CHE testing and 2-year follow-up. Cox regression was performed for time to OHE. In total, 700 patients (60 years, 84% men, model for end-stage liver disease 11) and 33% prior OHE underwent testing and follow-up. RESULTS: Major comorbidities were hypertension (54%), diabetes (35%), and depression (29%). Common medications were proton pump inhibitor (49%), beta-blockers (32%), and opioids (21%). Approximately 90 (40%) prior-OHE patients developed recurrence 93 (30,206) days post-testing predicted only by liverrelated variables. DISCUSSION: Demographics, cirrhosis characteristics, and opioid use, but not other comorbid conditions, were associated with CHE diagnosis and OHE progression.
Authors: Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong Journal: Hepatology Date: 2014-07-08 Impact factor: 17.425
Authors: M Kivipelto; E L Helkala; T Hänninen; M P Laakso; M Hallikainen; K Alhainen; H Soininen; J Tuomilehto; A Nissinen Journal: Neurology Date: 2001-06-26 Impact factor: 9.910
Authors: Jasmohan S Bajaj; Mette Lauridsen; Elliot B Tapper; Andres Duarte-Rojo; Robert S Rahimi; Puneeta Tandon; Debbie L Shawcross; Dominique Thabut; Radha K Dhiman; Manuel Romero-Gomez; Barjesh C Sharma; Sara Montagnese Journal: Am J Gastroenterol Date: 2020-07 Impact factor: 10.864
Authors: Rebecca F Gottesman; Andrea L C Schneider; Marilyn Albert; Alvaro Alonso; Karen Bandeen-Roche; Laura Coker; Josef Coresh; David Knopman; Melinda C Power; Andreea Rawlings; A Richey Sharrett; Lisa M Wruck; Thomas H Mosley Journal: JAMA Neurol Date: 2014-10 Impact factor: 18.302
Authors: Christian Labenz; Michael Nagel; Gerrit Toenges; Robert Kuchen; Jörn M Schattenberg; Max Hilscher; Yvonne Huber; Jens U Marquardt; Joachim Labenz; Peter R Galle; Marcus-Alexander Wörns Journal: Eur J Intern Med Date: 2020-08-29 Impact factor: 4.487
Authors: Jasmohan S Bajaj; Andres Duarte-Rojo; Jesse J Xie; Chathur Acharya; James B Wade; Carlos Robles; Leroy R Thacker; Christopher Flud; Andrew Fagan; Mauricio Garcia-Saenz-de-Sicilia; Melanie B White; Megan Kelly; Vy Nguyen; Edith A Gavis; Hugo E Vargas Journal: Clin Gastroenterol Hepatol Date: 2020-03-20 Impact factor: 11.382
Authors: Elliot B Tapper; Lilli Zhao; Samantha Nikirk; Jad Baki; Neehar D Parikh; Anna S Lok; Akbar K Waljee Journal: Am J Gastroenterol Date: 2020-12 Impact factor: 12.045